pediatic acute myeloid leukemia
Conditions
Interventions
DAH+ATRA:DAH induction+ATRA maintenance
DAE+ATRA:DAE induction+ATRA maintenance
DAH+Ara-c:DAH induction+Ara-c maintenance
DAE+Ara-c:DAE induction+Ara-c maintenance
Sponsors
Capital Medical University Beijing Children’s Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed of AML; 2. Patients younger than 18 years old; 3. Patients who haven't received pre-treatment, except for those who receive single IT injection or Hydroxycarbamide or small-dose Ara-c for Leukocytosis; 4. Patients who have signed the Informed Consent Form.
Exclusion criteria
Exclusion criteria: 1. Acute Promyelocytic Leukemia; 2. Junior Myelomonocytic Leukemia; 3. AML secondary to Fanconi Anemia; 4. AML secondary to Kostmann Syndrome; 5. AML secondary to Shwachman Syndrome; 6. AML secondary to other Bone Marrow Failure; 7. Patients who fail to receive systematic choemotherapy according to the protocol; 8. Patients who received any anti-tumor treatment within 2 weeks, except for those who received single IT injection or Hydroxycarbamide or small-dose Ara-c for Leukocytosis and have recovered from the adverse drug reactions; 9. Uncontrolled infection of bacteria, fungi, virus or any other pathogens (infection-related symptoms and sign progress despite proper use of antibiotics or any other treatment); 10. Patients complicated with psychiatric disease or any other diseases that could affect their safety and compliance, participation, follow-up or interpretation of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission State of Bone Marrow;Minimal Residual Disease;Three year's event free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effect of chemotherapy; | — |
Countries
China
Contacts
Public ContactZheng Huyong
Outcome results
None listed